Should I buy or sell OKYO Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OKYO Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OKYO shares. View OKYO analyst ratings or view top-rated stocks .

What is OKYO Pharma's stock price target for 2024?

1 brokers have issued 1-year target prices for OKYO Pharma's stock. Their OKYO share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price. View analysts price targets for OKYO or view top-rated stocks among Wall Street analysts .

How have OKYO shares performed in 2023?

OKYO Pharma's stock was trading at $1.91 on January 1st, 2023. Since then, OKYO shares have decreased by 12.8% and is now trading at $1.6650. View the best growth stocks for 2023 here .

When is OKYO Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 28th 2023. View our OKYO earnings forecast .

When did OKYO Pharma IPO?

(OKYO) raised $2 million in an initial public offering on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share.

Who are OKYO Pharma's major shareholders?

OKYO Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Barclays PLC (0.09%). View institutional ownership trends .

How do I buy shares of OKYO Pharma?

Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

OKYO Pharma Stock Price, News & Analysis (NASDAQ:OKYO)

$1.66

+0.04 (+2.46%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.63
▼
$1.73
50-Day Range: $1.57
▼
$2.75
52-Week Range: $0.92
▼
$7.00

Volume: 4,798 shs
Average Volume: 26,443 shs
Market Capitalization: $48.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

OKYO Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 140.2% Upside
$4.00 Price Target
Short Interest: Healthy
0.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$25,005 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

432nd out of 954 stocks

Biotechnology Industry

11th out of 24 stocks

3.5

Analyst's Opinion

Consensus Rating
OKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, OKYO Pharma has a forecasted upside of 140.2% from its current price of $1.67.
Amount of Analyst Coverage
OKYO Pharma has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.46% of the float of OKYO Pharma has been sold short.
Short Interest Ratio / Days to Cover
OKYO Pharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
OKYO Pharma does not currently pay a dividend.
Dividend Growth
OKYO Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OKYO.

2.7

News and Social Media Coverage

News Sentiment
OKYO Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for OKYO Pharma this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for OKYO on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OKYO Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,005.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 0.05% of the stock of OKYO Pharma is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for OKYO Pharma are expected to remain at ($0.40) per share in the coming year.

See Top Rated MarketRank™ Stocks Here

About OKYO Pharma Stock (NASDAQ:OKYO)

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OKYO Stock News Headlines

October 31, 2023 | msn.com

OKYO Pharma announces $5.84M cash raise and payables reduction

October 9, 2023 | finance.yahoo.com

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

September 15, 2023 | finance.yahoo.com

OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

September 13, 2023 | proactiveinvestors.com

OKYO Pharma announces share offering

September 13, 2023 | finance.yahoo.com

OKYO Pharma Announces Public Offering of Ordinary Shares

September 8, 2023 | proactiveinvestors.com

OKYO Pharma completes enrollment in Phase 2 clinical trial to treat dry eye disease

September 8, 2023 | barrons.com

Okyo Pharma Ltd.

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

August 30, 2023 | benzinga.com

Thinking about buying stock in T2 Biosystems, OKYO Pharma, Mullen Automotive, Digital Media Solutions, or Orbital Infrastructure Group?

August 30, 2023 | proactiveinvestors.com

OKYO Pharma dry eye disease trial reaches enrollment milestone; topline data expected by year-end

August 29, 2023 | finance.yahoo.com

OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule

August 15, 2023 | finance.yahoo.com

OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023

August 1, 2023 | investorplace.com

Why Is OKYO Pharma (OKYO) Stock Down 19% Today?

July 31, 2023 | msn.com

OKYO Pharma rebounds on withdrawal of equity offering

July 31, 2023 | finance.yahoo.com

OKYO Pharma Limited Announces Withdrawal of Public Offering

July 28, 2023 | marketwatch.com

OKYO Pharma Shares Rise 19% After Trial Agreement With Tufts Medical Center

July 28, 2023 | finance.yahoo.com

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center

July 27, 2023 | finance.yahoo.com

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer

June 6, 2023 | finance.yahoo.com

OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease

May 12, 2023 | benzinga.com

Phase 2 Trials Begin For Promising New Dry Eye Disease Treatment From OKYO Pharma

May 5, 2023 | nz.finance.yahoo.com

OKYO Pharma Limited (OKYO) stock price, news, quote & history – Yahoo Finance

May 3, 2023 | finance.yahoo.com

Uveitis Market to Witness Upsurge in Growth at a CAGR of 4.8% During the Study Period (2019-2032), Assesses DelveInsight

May 3, 2023 | proactiveinvestors.com

OKYO Pharma to address key conference with data on dry eye drug

May 3, 2023 | finance.yahoo.com

OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023

April 25, 2023 | proactiveinvestors.com

OKYO Pharma ready to kick off dry eye trial in the US

April 25, 2023 | finance.yahoo.com

OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

See More Headlines

Receive OKYO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/02/2023
Next Earnings (Estimated): 12/28/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OKYO
CUSIP: N/A
CIK: 1849296
Web: www.okyopharma.com
Phone: 44-20-7495-2379
Fax: N/A
Employees: 8
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +140.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.72
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.08) per share
Price / Book: -20.81

Miscellaneous

Outstanding Shares: 28,830,000
Free Float: 17,167,000
Market Cap: $48.00 million
Optionable: Not Optionable
Beta: 0.05

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Gary S. Jacob Ph.D. (Age 76)
CEO & Executive Director
Comp: $650k
Mr. Michael Paul Beck (Age 66)
Founder
Ms. Keeren Shah (Age 46)
Chief Financial Officer
Dr. William A. Clementi Ph.D.
Pharm.D., Chief Operating Officer
Dr. Rajkumar Patil Ph.D. (Age 64)
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OKYO Stock Analysis - Frequently Asked Questions

Should I buy or sell OKYO Pharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OKYO Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" OKYO shares.
View OKYO analyst ratings or view top-rated stocks.
What is OKYO Pharma's stock price target for 2024?: 1 brokers have issued 1-year target prices for OKYO Pharma's stock. Their OKYO share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price.
View analysts price targets for OKYO or view top-rated stocks among Wall Street analysts.
How have OKYO shares performed in 2023?: OKYO Pharma's stock was trading at $1.91 on January 1st, 2023. Since then, OKYO shares have decreased by 12.8% and is now trading at $1.6650.
View the best growth stocks for 2023 here.
When is OKYO Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, December 28th 2023.
View our OKYO earnings forecast.

When did OKYO Pharma IPO?: (OKYO) raised $2 million in an initial public offering on Tuesday, May 17th 2022. The company issued 625,000 shares at a price of $4.00 per share.
Who are OKYO Pharma's major shareholders?: OKYO Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Barclays PLC (0.09%).
View institutional ownership trends.
How do I buy shares of OKYO Pharma?: Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OKYO) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial